*Doheny Imaging Reading Center and Doheny Eye Institute, Pasadena, California;

†Department of Ophthalmology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California;

‡Retina Division, Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; and

§Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Reprint requests: Srinivas R. Sadda, MD, 150 N. Orange Grove Blvd., Suite 232, Pasadena, CA 91103; e-mail: [email protected]

Portions of this investigation were presented at ARVO 2022 (Denver, USA) on May 1, 2022, and EURETINA 2022 (Hamburg, Germany) on September 4, 2022.

O. Nanegrungsunk: Allergan, Bayer, Novartis, Roche, Santen; G. Corradetti: Nidek; P. Phinyo: none; J. Choovuthayakorn: Bayer; S. R. Sadda: 4DMT, Allergan, Amgen, Apellis, Astellas, Bayer, Carl Zeiss Meditec, CenterVue, Genetech/Roche, Heidelberg, Iveric, Merck, Nidek, Novartis, Optos, Oxurion, Regeneron, Topcon.